A dialog on the first 20 years of PML research and the next 20 ahead

Rosa Bernardi, Pier Paolo Pandolfi

Research output: Contribution to journalArticlepeer-review


This introductory article has been written in the form of a conversation between Pier Paolo Pandolfi, Director of the Cancer Center of Beth Israel Deaconess Medical Center in Boston, and Rosa Bernardi, a former post-doctoral fellow in the laboratory of Dr. Pandolfi, now principal investigator at San Raffaele Scientific Institute in Milan, Italy. We have chosen this atypical review format because we want to offer to our readers a more direct and personal perspective on the first 20 years of research over the promyelocytic leukemia gene. This article begins as an interview, but soon transforms into a dialog where we exchange our thoughts on a number of issues around the past, present, and future research over the biology of PML. We were particularly keen on emphasizing the aspects that we find most interesting or challenging, therefore, we warn our readers that this will not be a comprehensive essay but rather a very personal view of what has been, is, and will be exciting and interesting in the PML world, in our opinion.

Original languageEnglish
Article numberArticle 23
JournalFrontiers in Oncology
Volume4 FEB
Publication statusPublished - 2014


  • Apoptosis
  • Leukemia
  • Nuclear bodies
  • PML
  • Tumor suppressor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'A dialog on the first 20 years of PML research and the next 20 ahead'. Together they form a unique fingerprint.

Cite this